Dalkon Shield fund plans $1 billion surplus payout:
This article was originally published in Clinica
With only 6,000 claims still pending, the Dalkon Shield Claimants Trust is projecting a surplus of $1,000 million, which it intends to share among the 49,176 women whose claims for injuries from the contraceptive device have already been settled. The trust was set up in 1989 to resolve 192,000 claims from women believed to have suffered pelvic infections and damage to reproductive organs after using the IUD. Manufacturer AH Robins was sold to American Home Products the same year following bankruptcy court reorganisation.
You may also be interested in...
Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.
The US agency will host a two-day meeting to discuss the evolution of artificial intelligence technology used to analyze radiological images when diagnosing patients and in advising radiologists to take optimal pictures. The takeaways from the meeting will be used by the FDA to help it develop its thinking on how to regulate such technology.